Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John de Groot

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Neuro-Oncology|November 19, 2024
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responsesCalixto-Hope G Lucas, Nadeem N Al-Adli, Jacob S Young, et al.
The Lancet. Oncology|October 3, 2024
A brave new framework for glioma drug developmentKelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, et al.
Nature Medicine|December 12, 2018
The molecular landscape of glioma in patients with Neurofibromatosis 1Fulvio D'Angelo, Michele Ceccarelli, Tala, et al.
Neuro-Oncology|August 30, 2025
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy ConsortiumChetan Bettegowda, Houtan Noushmehr, Alessandra Affinito, et al.
Acta Neuropathologica|August 9, 2022
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1Calixto-Hope G Lucas, Emily A Sloan, Rohit Gupta, et al.
Cancer Discovery|August 16, 2023
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic PathwaysSriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Neuro-Oncology|November 19, 2024
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responsesCalixto-Hope G Lucas, Nadeem N Al-Adli, Jacob S Young, et al.
The Lancet. Oncology|October 3, 2024
A brave new framework for glioma drug developmentKelly M Hotchkiss, Philipp Karschnia, Karisa C Schreck, et al.
Nature Medicine|December 12, 2018
The molecular landscape of glioma in patients with Neurofibromatosis 1Fulvio D'Angelo, Michele Ceccarelli, Tala, et al.
Neuro-Oncology|August 30, 2025
Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy ConsortiumChetan Bettegowda, Houtan Noushmehr, Alessandra Affinito, et al.
Acta Neuropathologica|August 9, 2022
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1Calixto-Hope G Lucas, Emily A Sloan, Rohit Gupta, et al.
Cancer Discovery|August 16, 2023
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic PathwaysSriram Venneti, Abed Rahman Kawakibi, Sunjong Ji, et al.
Pageof 9